HST Global (HSTC) 10-K 5 Apr 24 2023 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2023	Apr. 05, 2024	Jun. 30, 2023
Details
Registrant CIK	0000797564
Fiscal Year End	--12-31
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Shell Company	false
Entity Ex Transition Period	false
Entity Voluntary Filers	No
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Document Annual Report	true
Document Transition Report	false
Document Type	10-K
Document Period End Date	Dec. 31, 2023
Securities Act File Number	000-15303
Entity Registrant Name	HST GLOBAL, INC.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	73-1215433
Entity Address, Address Line One	150 Research Drive
Entity Address, City or Town	Hampton
Entity Address, State or Province	VA
Entity Address, Postal Zip Code	23666
City Area Code	757
Local Phone Number	766-6100
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 96,779
Entity Common Stock, Shares Outstanding		5,248,582

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 1,526	$ 190
Total Current Assets	1,526	190
Total Assets	1,526	190
LIABILITIES AND STOCKHOLDERS' DEFICIT
Total Liabilities	593,593	446,047
Stockholders' Deficit
Preferred stock; 10,000,000 shares authorized, at $0.001 par value, no shares issued and outstanding at December 31, 2023 and 2022	0	0
Common stock; 200,000,000 shares authorized, at $0.001 par value, 5,248,582 shares issued and outstanding at December 31, 2023 and 2022	5,248	5,248
Additional paid-in capital	5,417,236	5,417,236
Accumulated deficit	(6,014,551)	(5,868,341)
Total Stockholders' Deficit	(592,067)	(445,857)
Current Liabilities
Accounts payable and accrued expenses - related parties	2,275	2,275
Accrued officer compensation	480,000	360,000
Loans or advances from related party	98,319	76,077
Accrued related party interest	12,999	7,695
Total Current Liabilities	593,593	446,047
Total Liabilities and Stockholders' Deficit	$ 1,526	$ 190

CONSOLIDATED BALANCE SHEETS - P

CONSOLIDATED BALANCE SHEETS - Parenthetical - $ / shares	Dec. 31, 2023	Dec. 31, 2022
CONSOLIDATED BALANCE SHEETS
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares, Issued	5,248,582
Common Stock, Shares, Outstanding	5,248,582

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 0	$ 0
Operating Expenses
Consulting, related party	120,000	120,000
General and administrative	20,907	21,035
Total Operating Expenses	140,907	141,035
Net Loss from Operations	(140,907)	(141,035)
Other Income (Expense)
Interest expense	(5,303)	(4,039)
Total Other Expense	(5,303)	(4,039)
NET LOSS	$ (146,210)	$ (145,074)
Earnings (Loss) Per Share: Basic and Diluted - Common	$ (0.03)	$ (0.03)
Weighted Average Shares Outstanding: Basic and Diluted - Common	5,248,582	5,248,582

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - 12 months ended Dec. 31, 2023 - USD ($)	Common Stock	Additional Paid-in Capital	Retained Earnings	Total
Balance, December 31, 2022 at Dec. 31, 2022	$ 5,248	$ 5,417,236	$ (5,868,341)	$ (445,857)
Net Loss	0	0	(146,210)	(146,210)
Balance, December 31, 2023 at Dec. 31, 2023	$ 5,248	$ 5,417,236	$ (6,014,551)	$ (592,067)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash Flows from Operating Activities
Net loss	$ (146,210)	$ (145,074)
Changes in operating assets and liabilities
Accrued officer compensation	120,000	120,000
Accrued related party interest	5,304	4,039
Net Cash used in Operating Activities	(20,906)	(21,035)
Cash Flows from Investing Activities
Net Cash used in Investing Activities	0	0
Cash Flows from Financing Activities
Proceeds from notes payable - related party	22,242	21,000
Net Cash provided by Financing Activities	22,242	21,000
Net change in Cash and Cash Equivalents	1,336	(35)
Cash and Cash Equivalents at Beginning of Year	190	225
Cash and Cash Equivalents at End of Year	1,526	190
Supplemental Disclosures of Cash Flow Information
Cash paid for interest	0	0
Cash paid for taxes	$ 0	$ 0

Financial Statement Contents

Financial Statement Contents	12 Months Ended
	Dec. 31, 2023
Notes
Financial Statement Contents	Description Page Reports of Independent Registered Public Accounting Firms ( PCAOB Firm ID 76 8 Consolidated Balance Sheets 9 Consolidated Statements of Operations 10 Consolidated Statements of Stockholders' Deficit 11 Consolidated Statements of Cash Flows 12 Notes to Consolidated Financial Statements 13

Auditor Information

Auditor Information	12 Months Ended
	Dec. 31, 2023
Notes
Auditor Information	/s/ Turner, Stone & Company, LLP We have served as HST Global, Inc.’s auditor since 2020. Dallas, Texas April 05, 2024

NOTE 1 - ORGANIZATION AND PRINC

NOTE 1 - ORGANIZATION AND PRINCIPAL ACTIVITIES	12 Months Ended
	Dec. 31, 2023
Notes
NOTE 1 - ORGANIZATION AND PRINCIPAL ACTIVITIES	NOTE 1 - ORGANIZATION AND PRINCIPAL ACTIVITIES HST Global, Inc. (“the Company”) was incorporated on April 11, 1984 under the laws of the State of Delaware under the name of NT Holding Corporation. The Company has made several acquisitions and disposals of various business entities and activities. On May 9, 2008, the Company entered into a Merger and share exchange agreement with Health Source Technologies, Inc. This business acquisition has been accounted for as a reverse merger or recapitalization of Health Source Technologies, Inc (“Health Source”). At the time of the merger NT Holding Corporation had disposed of its assets and liabilities and had minimal operations. Immediately after the acquisition the Company changed its name to HST Global, Inc. Health Source Technologies, Inc. was incorporated under the laws of the State of Nevada on August 6, 2007. The Company is currently headquartered in Hampton, Virginia. The Company is an integrated health and wellness biotechnology company with a plan to develop and/or acquire a network of wellness centers worldwide with the primary focus on homeopathic and alternative treatments of late stage cancer and other life threatening diseases. In addition, the Company intends to acquire innovative products for the treatment of life threatening diseases. The Company primarily focuses on homeopathic and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer and/or life threatening diseases. To date we have been unable to initiate our original business plan. While we are continuing to seek opportunities to do so, we are also seeking other opportunities to integrate assets, rights, or other potential revenue streams.

NOTE 2 - SIGNIFICANT ACCOUNTING

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2023
Notes
NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements and related notes include the activity of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) to Form 10-K. Principles of Consolidation The consolidated financial statements include our wholly-owned subsidiary, Health Source. Intercompany balances and transactions have been eliminated. Accounting Method The Company’s financial statements are prepared using the accrual method of accounting. The Company has elected a December 31 year end. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the consolidated statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Income Taxes The Company accounts for income taxes in accordance with accounting guidance now codified as FASB ASC 740, " Income Taxes The Company applies the provisions of ASC 740, “ Accounting for Uncertainty in Income Taxes Basic and Diluted Loss Per Share The computations of basic loss per share of common stock are based on the weighted average number of shares outstanding at the date of the consolidated financial statements. The Company computes net income (loss) per share in accordance with ASC 260. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the consolidated statement of operations. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is antidilutive. The Company had no common stock equivalents outstanding as of December 31, 2023 and 2022. Stock-Based Compensation The Company adopted ASC 718, “Stock Compensation Fair Value of Financial Instruments ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under this standard certain assets and liabilities must be measured at fair value, and disclosures are required for items measured at fair value. The Company currently does not have non-financial assets or non-financial liabilities that are required to be measured at fair value on a recurring basis. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. The fair value of the Company’s cash is based on quoted prices and therefore classified as Level 1. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. Recently Issued Accounting Pronouncements Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s consolidated financial statements.

NOTE 3 - GOING CONCERN

NOTE 3 - GOING CONCERN	12 Months Ended
	Dec. 31, 2023
Notes
NOTE 3 - GOING CONCERN	NOTE 3 – GOING CONCERN The Company’s consolidated financial statements are prepared using U.S. GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business within one year after the date these consolidated financial statements were issued. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. There is substantial doubt that the Company can continue as a going concern for a period of one year from the issuance of these consolidated financial statements. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations. Management’s plan to support the Company in its operations and to maintain its business strategy is to raise funds through public offerings and to rely on officers and directors to perform essential functions with minimal compensation. If the Company does not raise all of the money it needs from public offerings, it will have to find alternative sources, such as a second public offering, a private placement of securities, or loans from its officers, directors or others. If the Company requires additional cash and is unable to raise it, it will either have to suspend operations until the cash is raised, or cease business entirely. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

NOTE 4 - ACCOUNTS PAYABLE AND A

NOTE 4 - ACCOUNTS PAYABLE AND ACCURED EXPENSES - RELATED PARTIES	12 Months Ended
	Dec. 31, 2023
Notes
NOTE 4 - ACCOUNTS PAYABLE AND ACCURED EXPENSES - RELATED PARTIES	NOTE 4 – ACCOUNTS PAYABLE AND ACCURED EXPENSES – RELATED PARTIES Accounts payable and accrued expenses - related parties consist of the following at December 31: December 31, 2023 December 31, 2022 The Health Network, Inc. $ 2,275 $ 2,275 Ronald Howell 480,000 360,000 Total $ 482,275 $ 360,275 Please see Note 5 for further explanation of these liabilities.

NOTE 5 - RELATED PARTY TRANSACT

NOTE 5 - RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2023
Notes
NOTE 5 - RELATED PARTY TRANSACTIONS	NOTE 5 - RELATED PARTY TRANSACTIONS Notes Payable – Related Parties Total related party notes payable as of December 31, 2023 and 2022 were $98,319 and $76,077. During the year ended December 31, 2022, the Company received $22,242 in additional cash loans. Executive Offices The Company's executive offices are located at 150 Research Dr., Hampton VA. These offices are leased by The Health Network, Inc. ("THN"), of which Ron Howell is President. THN allows the Company to use the office space without a formal sublease or rental agreement. Consulting Agreements The Company has entered into a consulting agreement with Mr. Howell, President of the Company, whereby the Company agreed to pay Mr. Howell $10,000 per month for consulting services through December 31, 2010. The Company had agreed to continue to engage Mr. Howell as a consultant until his consulting services are no longer required. The agreement was suspended from July, 2019 through December, 2019 due to the pendency of the APA, and has resumed beginning in January, 2020 due to the termination of the APA. During the years ended December 31, 2023 and 2022, the Company recognized $120,000 for consulting fees in each year for Ronald Howell. As of December 31, 2023 and 2022, the Company owed Mr. Howell $480,000 and $360,000 under the consulting agreement.

NOTE 6 - COMMON STOCK

NOTE 6 - COMMON STOCK	12 Months Ended
	Dec. 31, 2023
Notes
NOTE 6 - COMMON STOCK	NOTE 6 – COMMON STOCK None.

NOTE 7 - INCOME TAXES

NOTE 7 - INCOME TAXES	12 Months Ended
	Dec. 31, 2023
Notes
NOTE 7 - INCOME TAXES	NOTE 7 – INCOME TAXES The Company follows ASC 740, under which deferred income taxes reflect the net effect of (a) temporary difference between carrying amounts of assets and liabilities for financial purposes and the amounts used for income tax reporting purposes, and (b) net operating loss carry-forwards. No net provision for refundable Federal income tax has been made in the accompanying consolidated statement of operations because no recoverable taxes were paid previously. Similarly, no deferred tax asset attributable to the net operating loss carry-forward has been recognized, as it is not deemed likely to be realized. The cumulative tax effect at the expected rate of 21 percent of significant items comprising our net deferred tax amount is as follows: Year ended December 31, 2023 Year ended December 31, 2022 Income tax benefit attributable to: Net operating loss $ (30,704) $ (30,466) Change in valuation allowance 30,704 30,466 Net refundable amount $ - $ - The cumulative tax effect at the expected rate of 21 percent (for 2023 & 2022) of significant items comprising our net deferred tax amount is as follows: December 31, 2023 December 31, 2022 Deferred tax asset attributable to: Net operating loss carry forwards $ (1,284,447) $ (1,253,743) Common stock issued for services 113,692 113,692 Valuation allowance 1,170,755 1,140,051 Net deferred tax asset $ - $ - The Company’s zero percent effective tax rate for each year, as compared to the 21 percent statutory rate, results from non-deductible stock based compensation and the change in valuation allowance. At December 31, 2023, the Company had an unused net operating loss carry-forward of approximately $5,428,815 that is available to offset future taxable income; the loss carry-forward will begin to expire in 2027.

NOTE 8 - SUBSEQUENT EVENTS

NOTE 8 - SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2023
Notes
NOTE 8 - SUBSEQUENT EVENTS	NOTE 8 – SUBSEQUENT EVENTS In accordance with ASC 855, Subsequent Events

NOTE 2 - SIGNIFICANT ACCOUNTI_2

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES: Basis of Presentation (Policies)	12 Months Ended
	Dec. 31, 2023
Policies
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements and related notes include the activity of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) to Form 10-K.

NOTE 2 - SIGNIFICANT ACCOUNTI_3

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES: Principles of Consolidation (Policies)	12 Months Ended
	Dec. 31, 2023
Policies
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include our wholly-owned subsidiary, Health Source. Intercompany balances and transactions have been eliminated.

NOTE 2 - SIGNIFICANT ACCOUNTI_4

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES: Accounting Method (Policies)	12 Months Ended
	Dec. 31, 2023
Policies
Accounting Method	Accounting Method The Company’s financial statements are prepared using the accrual method of accounting. The Company has elected a December 31 year end.

NOTE 2 - SIGNIFICANT ACCOUNTI_5

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES: Use of Estimates (Policies)	12 Months Ended
	Dec. 31, 2023
Policies
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

NOTE 2 - SIGNIFICANT ACCOUNTI_6

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Policies)	12 Months Ended
	Dec. 31, 2023
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents We maintain cash balances in non-interest-bearing accounts, which do not currently exceed federally insured limits. For the purpose of the consolidated statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents.

NOTE 2 - SIGNIFICANT ACCOUNTI_7

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES: Income Taxes (Policies)	12 Months Ended
	Dec. 31, 2023
Policies
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with accounting guidance now codified as FASB ASC 740, " Income Taxes The Company applies the provisions of ASC 740, “ Accounting for Uncertainty in Income Taxes

NOTE 2 - SIGNIFICANT ACCOUNTI_8

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES: Basic and Diluted Income (Loss) Per Share (Policies)	12 Months Ended
	Dec. 31, 2023
Policies
Basic and Diluted Income (Loss) Per Share	Basic and Diluted Loss Per Share The computations of basic loss per share of common stock are based on the weighted average number of shares outstanding at the date of the consolidated financial statements. The Company computes net income (loss) per share in accordance with ASC 260. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the consolidated statement of operations. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is antidilutive. The Company had no common stock equivalents outstanding as of December 31, 2023 and 2022.

NOTE 2 - SIGNIFICANT ACCOUNTI_9

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES: Stock-Based Compensation (Policies)	12 Months Ended
	Dec. 31, 2023
Policies
Stock-Based Compensation	Stock-Based Compensation The Company adopted ASC 718, “Stock Compensation

NOTE 2 - SIGNIFICANT ACCOUNT_10

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES: Fair Value of Financial Instruments (Policies)	12 Months Ended
	Dec. 31, 2023
Policies
Fair Value of Financial Instruments	Fair Value of Financial Instruments ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under this standard certain assets and liabilities must be measured at fair value, and disclosures are required for items measured at fair value. The Company currently does not have non-financial assets or non-financial liabilities that are required to be measured at fair value on a recurring basis. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. The fair value of the Company’s cash is based on quoted prices and therefore classified as Level 1. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability.

NOTE 2 - SIGNIFICANT ACCOUNT_11

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES: Recently Issued Accounting Pronouncements (Policies)	12 Months Ended
	Dec. 31, 2023
Policies
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s consolidated financial statements.

NOTE 5 - RELATED PARTY TRANSA_2

NOTE 5 - RELATED PARTY TRANSACTIONS: NOTE 5 - RELATED PARTY TRANSACTIONS (Policies)	12 Months Ended
	Dec. 31, 2023
NOTE 5 - RELATED PARTY TRANSACTIONS	NOTE 5 - RELATED PARTY TRANSACTIONS Notes Payable – Related Parties Total related party notes payable as of December 31, 2023 and 2022 were $98,319 and $76,077. During the year ended December 31, 2022, the Company received $22,242 in additional cash loans. Executive Offices The Company's executive offices are located at 150 Research Dr., Hampton VA. These offices are leased by The Health Network, Inc. ("THN"), of which Ron Howell is President. THN allows the Company to use the office space without a formal sublease or rental agreement. Consulting Agreements The Company has entered into a consulting agreement with Mr. Howell, President of the Company, whereby the Company agreed to pay Mr. Howell $10,000 per month for consulting services through December 31, 2010. The Company had agreed to continue to engage Mr. Howell as a consultant until his consulting services are no longer required. The agreement was suspended from July, 2019 through December, 2019 due to the pendency of the APA, and has resumed beginning in January, 2020 due to the termination of the APA. During the years ended December 31, 2023 and 2022, the Company recognized $120,000 for consulting fees in each year for Ronald Howell. As of December 31, 2023 and 2022, the Company owed Mr. Howell $480,000 and $360,000 under the consulting agreement.
Notes Payable - Related Parties
NOTE 5 - RELATED PARTY TRANSACTIONS	Notes Payable – Related Parties Total related party notes payable as of December 31, 2023 and 2022 were $98,319 and $76,077. During the year ended December 31, 2022, the Company received $22,242 in additional cash loans.
Executive Offices
NOTE 5 - RELATED PARTY TRANSACTIONS	Executive Offices The Company's executive offices are located at 150 Research Dr., Hampton VA. These offices are leased by The Health Network, Inc. ("THN"), of which Ron Howell is President. THN allows the Company to use the office space without a formal sublease or rental agreement.
Consulting Agreements
NOTE 5 - RELATED PARTY TRANSACTIONS	Consulting Agreements The Company has entered into a consulting agreement with Mr. Howell, President of the Company, whereby the Company agreed to pay Mr. Howell $10,000 per month for consulting services through December 31, 2010. The Company had agreed to continue to engage Mr. Howell as a consultant until his consulting services are no longer required. The agreement was suspended from July, 2019 through December, 2019 due to the pendency of the APA, and has resumed beginning in January, 2020 due to the termination of the APA. During the years ended December 31, 2023 and 2022, the Company recognized $120,000 for consulting fees in each year for Ronald Howell. As of December 31, 2023 and 2022, the Company owed Mr. Howell $480,000 and $360,000 under the consulting agreement.

NOTE 7 - INCOME TAXES_ Schedule

NOTE 7 - INCOME TAXES: Schedule of Components of Income Tax Expense (Benefit) (Tables)	12 Months Ended
	Dec. 31, 2023
Tables/Schedules
Schedule of Components of Income Tax Expense (Benefit)	The cumulative tax effect at the expected rate of 21 percent of significant items comprising our net deferred tax amount is as follows: Year ended December 31, 2023 Year ended December 31, 2022 Income tax benefit attributable to: Net operating loss $ (30,704) $ (30,466) Change in valuation allowance 30,704 30,466 Net refundable amount $ - $ -

NOTE 7 - INCOME TAXES_ Schedu_2

NOTE 7 - INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2023
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities	The cumulative tax effect at the expected rate of 21 percent (for 2023 & 2022) of significant items comprising our net deferred tax amount is as follows: December 31, 2023 December 31, 2022 Deferred tax asset attributable to: Net operating loss carry forwards $ (1,284,447) $ (1,253,743) Common stock issued for services 113,692 113,692 Valuation allowance 1,170,755 1,140,051 Net deferred tax asset $ - $ -

Financial Statement Contents (D

Financial Statement Contents (Details)	12 Months Ended
	Dec. 31, 2023
Details
Auditor Firm ID	76

Auditor Information (Details)

Auditor Information (Details)	12 Months Ended
	Dec. 31, 2023
Details
Auditor Name	Turner, Stone & Company, LLP
Auditor Location	Dallas, Texas

NOTE 7 - INCOME TAXES_ Schedu_3

NOTE 7 - INCOME TAXES: Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income tax benefit attributable to
Net operating loss	$ (30,704)	$ (30,466)
Change in valuation allowance	30,704	30,466
Net refundable amount	$ 0	$ 0

NOTE 7 - INCOME TAXES_ Schedu_4

NOTE 7 - INCOME TAXES: Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Deferred tax asset attributable to
Net operating loss carry forwards	$ (1,284,447)	$ (1,253,743)
Common stock issued for services	113,692	113,692
Valuation allowance	1,170,755	1,140,051
Net deferred tax asset	$ 0	$ 0